{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:25:25Z","timestamp":1764739525393,"version":"3.46.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Solid cancer patients are at increased risk of severe COVID-19 and may benefit from repeated booster doses of SARS-CoV-2 mRNA vaccines. Beyond neutralizing antibody titers, recent evidence highlights the induction of spike-specific IgG4 after multiple vaccine doses, a phenomenon potentially linked to immune tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the humoral response following the administration of the fourth and fifth dose of the Comirnaty Omicron XBB.1.5 mRNA vaccine in 48 patients with solid tumors undergoing active or recent anticancer treatment, compared with age-matched controls (n=24). Serum samples were collected before (T1) and three weeks after vaccination (T2). IgG against the spike receptor-binding-domain (IgG-RBD-S), spike-specific IgM (IgM-S), and IgG4 (IgG4-S) were quantified using standardized assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Booster vaccination induced a robust increase in neutralizing IgG-RBD-S, with a median 4.6-fold rise at T2 (9568.9 vs. 2086.4 BAU\/mL). Notably, high baseline titers at T1 confirmed antibody persistence at about one year after the third dose. IgG-RBD-S levels were higher in patients receiving the fifth compared to the fourth dose, supporting a cumulative dose-dependent effect. IgM-S positivity correlated with significantly stronger neutralizing responses. IgG4-S significantly increased post-vaccination (8.7 to 28.3 ng\/mL), but no differences were observed between cancer patients and controls, nor between the fourth and fifth dose, suggesting a lack of further IgG4 accumulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Repeated booster doses elicit strong and durable neutralizing antibody responses in solid cancer patients. It seems that variant-adapted formulations may mitigate IgG4 accumulation, thus ideally moderating tolerance associated with IgG4 by introducing antigenic novelty. These findings support continued booster administration and monitoring of humoral responses in oncologic populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1699177","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:23Z","timestamp":1764739223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Chiara","family":"Piubelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Zipeto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Caldrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rizzolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrine","family":"Barbero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Vezzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Gianesini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Tiberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Stefania","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Verz\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Nicolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico Giovanni","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/evolut\/qpae041","article-title":"Endemic does not mean constant as SARS-CoV-2 continues to evolve","volume":"78","author":"Otto","year":"2024","journal-title":"Evolution"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-coV-2 vaccine\u2013induced immunity: A systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1002\/mco2.675","article-title":"The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies","volume":"5","author":"Lu","year":"2024","journal-title":"MedComm"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/v15040944","article-title":"Evolution of SARS-coV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies","volume":"15","author":"Zabidi","year":"2023","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf074","article-title":"COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review","volume":"30","author":"Aurer","year":"2025","journal-title":"Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.019","article-title":"Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry","volume":"170","author":"Cortellini","year":"2022","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2400034","DOI":"10.1200\/OA-24-00034","article-title":"Differential survival among patients with cancer by COVID-19 vaccination status: an analysis of the ASCO COVID-19 registry","volume":"1","author":"Kirkwood","year":"2024","journal-title":"JCO Oncol Adv"},{"key":"B9","unstructured":"Statement on the antigen composition of COVID-19 vaccines\n          \n          2024"},{"key":"B10","unstructured":"EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 20242025\n          \n          2024"},{"key":"B11","unstructured":"Classificazione, ai sensi dell\u2019articolo 12, comma 5, della legge 8 novembre 2012, n. 189, del medicinale per uso umano, a base di bretovameran, \u00abComirnaty JN.1\u00bb\n          \n          2024"},{"key":"B12","unstructured":"Raccomandazioni 2024\u20132025 per la vaccinazione anti COVID-19\n          \n          2024"},{"key":"B13","unstructured":"Monitoraggio indipendente della campagna vaccinale anti-COVID-19\n          \n          2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2357424","article-title":"Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis","volume":"20","author":"Hua","year":"2024","journal-title":"Hum Vaccines Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111207","article-title":"Humoral response to SARS-coV-2 vaccine-boost in cancer patients: A case series from a southern european cancer center","volume":"12","author":"Oliveira","year":"2024","journal-title":"Vaccines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.03.017","article-title":"COVID-19 vaccination in cancer patients: Immune responses one year after the third dose","volume":"42","author":"Campagna","year":"2024","journal-title":"Vaccine"},{"key":"B17","first-page":"1089944","article-title":"Humoral effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments","volume-title":"Front. Oncol","author":"Piubelli","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010076","article-title":"Humoral response and safety after a fourth dose of the SARS-coV-2 BNT162b2 vaccine in cancer patients undergoing active treatment\u2014Results of a prospective observational study","volume":"12","author":"Citterio","year":"2024","journal-title":"Vaccines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126547","article-title":"Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer","volume":"46","author":"Body","year":"2025","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11071166","article-title":"Humoral and cellular immunity following five doses of COVID-19 vaccines in solid organ transplant recipients: A systematic review and meta-analysis","volume":"11","author":"Alotaibi","year":"2023","journal-title":"Vaccines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2023.11.028","article-title":"The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines","volume":"139","author":"Yoshimura","year":"2024","journal-title":"Int J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"eade2798","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1020844","article-title":"mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine","volume":"13","author":"Buhre","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107990","article-title":"Class switch toward IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccinees","volume":"159","author":"Siebner","year":"2025","journal-title":"Int J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/v17050666","article-title":"Impact of vaccine-elicited anti-spike igG4 antibodies on fc-effector functions against SARS-coV-2","volume":"17","author":"Dionne","year":"2025","journal-title":"Viruses"},{"key":"B26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41541-024-00919-8","article-title":"Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding","volume":"9","author":"Hartley","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106543","article-title":"Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform\u2013specific priming and immune imprinting","volume":"91","author":"Kalkeri","year":"2025","journal-title":"J Infect"},{"key":"B28","doi-asserted-by":"publisher","first-page":"eadg7327","DOI":"10.1126\/sciimmunol.adg7327","article-title":"Is it bad, is it good, or is IgG4 just misunderstood","volume":"8","author":"Pillai","year":"2023","journal-title":"Sci Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.8.4718","article-title":"T regulatory-1 cells induce igG4 production by B cells: role of IL-10","volume":"174","author":"Satoguina","year":"2005","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78891","article-title":"Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs","volume":"124","author":"Akdis","year":"2014","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1309997","article-title":"Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations","volume":"14","author":"Akhtar","year":"2023","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105479","article-title":"Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice","volume":"25","author":"Gao","year":"2022","journal-title":"iScience"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11050991","article-title":"IgG4 antibodies induced by repeated vaccination may generate immune tolerance to the SARS-coV-2 spike protein","volume":"11","author":"Uversky","year":"2023","journal-title":"Vaccines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fc\u03b3 receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human igG4 antibodies by dynamic fab arm exchange","volume":"317","author":"Van Der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106317","article-title":"Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines","volume":"89","author":"Marchese","year":"2024","journal-title":"J Infect"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106473","article-title":"Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections","volume":"90","author":"Mart\u00edn P\u00e9rez","year":"2025","journal-title":"J Infect"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01264-1","article-title":"mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review","volume":"24","author":"Boretti","year":"2024","journal-title":"Clin Exp Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12979-024-00466-9","article-title":"Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults","volume":"21","author":"Gelderloos","year":"2024","journal-title":"Immun Ageing"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17122006","article-title":"Repeated COVID-19 vaccination as a poor prognostic factor in pancreatic cancer: A retrospective, single-center cohort study","volume":"17","author":"Abue","year":"2025","journal-title":"Cancers"},{"key":"B42","first-page":"1024","article-title":"Eight edition\/editor-in-chief, Mahul B. Amin, MD, FCAP; editors, Stephen B. Edge, MD, FACS [and 16 others]; Donna M. Gress, RHIT, CTR-Technical editor; Laura R. Meyer, CAPM-Managing editor","volume-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115659","article-title":"Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection","volume":"103","author":"Van Elslande","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"12403","DOI":"10.1038\/s41598-022-16402-0","article-title":"Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients","volume":"12","author":"Movsisyan","year":"2022","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-021-00039-7","article-title":"Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus na\u00efve","volume":"1","author":"Dalle Carbonare","year":"2021","journal-title":"Commun Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103888","article-title":"SARS-CoV-2 vaccination elicits unconventional IgM specific responses in na\u00efve and previously COVID-19-infected individuals","volume":"77","author":"Ruggiero","year":"2022","journal-title":"EBioMedicine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104471","article-title":"Subjects who developed SARS-CoV-2 specific IgM after vaccination show a longer humoral immunity and a lower frequency of infection","volume":"89","author":"Piubelli","year":"2023","journal-title":"EBioMedicine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116000","article-title":"Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses","volume":"44","author":"Tam","year":"2025","journal-title":"Cell Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"eadj9945","DOI":"10.1126\/sciadv.adj9945","article-title":"Waning immunity and IgG4 responses following bivalent mRNA boosting","volume":"10","author":"Lasrado","year":"2024","journal-title":"Sci Adv"},{"key":"B50","doi-asserted-by":"publisher","first-page":"eads1482","DOI":"10.1126\/sciadv.ads1482","article-title":"Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant","volume":"11","author":"Aurelia","year":"2025","journal-title":"Sci Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1699177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:25Z","timestamp":1764739225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1699177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2025.1699177"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1699177","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1699177"}}